Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/8/2013

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast- 2Q Fiscal Year 2013 Financial Results Press Release

2/14/2013 at 7:30 a.m. ET- 2Q Fiscal Year 2013 Conference Call-Live

2/14/2013 at 11:00 a.m. ET  Domestic Dial-In Number

1-888-539-3678  International Dial-In Number

1-719-325-2329  Passcode

4795478- 2Q Fiscal Year 2013 Conference Call-Replay

2/14/2013-2/21/2013  Domestic Dial-In Number

1-888-203-1112  International Dial-In Number

1-719-457-0820  Passcode

4795478  Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
2. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
4. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
8. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
11. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... 25 BN,ImmunoTherapeutics, Inc. announced today that the ... licensed from the National Institutes of,Health (NIH) is ... the,excellent safety and efficacy results previously reported, will ... on February 26-28, 2009 in,Orlando, Florida. , ...
... 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ... researching,developing, manufacturing and marketing biopharmaceutical products, today,announced that ... quarter and,full year ended December 31, 2008 after ... , Following the earnings ...
... Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled ... patch Phase III program. The program consists of ... Cerimon,s diclofenac patch. The studies will assess the ... placebo for the treatment of acute pain caused by ...
Cached Biology Technology:BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 33SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:9/2/2014)... non-indigenous women in Queensland, Australia, is closing, however indigenous ... preventable causes, find researchers in a new study published ... of Obstetrics and Gynaecology ( BJOG ). , ... Data Collection and looked at 881,211 singleton births from ... in stillbirth rates over time among indigenous (Australian Aboriginal ...
(Date:9/2/2014)... blogs: Earthquake rupture through a U.S. suburb , ... California Davis in the hours and days after the ... understand why the earthquake caused so much damage in ... Earth blog, hosted by the American Geophysical Union. ... Rovers: The Next Places to Direct Our Curiosity ...
(Date:9/2/2014)... 3, The Field Museum will present the prestigious Parker/Gentry ... his commitment to biodiversity conservation awareness. The Parker/Gentry Award ... outstanding individual, team or organization whose efforts have had ... heritage and whose actions can serve as a model ... Mongabay.com, an environmental science and conservation news website that ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 ... from human DNA fragmentation factor (DFF). The sequence of ... - P - K - S - V - K ... - S - P - R - K(18). ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... High Throughput Processing of Microarrays Using the ... Frame multiple slide plate is designed to ... corresponding multi-well incubation chambers in a microplate ... The footprint dimensions meet the standards recommended ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: